Avita Medical Ltd. (ASX: AVH), the regenerative medicine company, announced today that it has expanded its sales and marketing operations into three new countries: Russia, The Netherlands andPortugal. The Company has previously established commercial operations in Australia, France,Germany and the United Kingdom.
The Company has been focussing its international sales and marketing efforts on working closely with key, highly regarded surgeons in these countries in order to develop a select group of Key Opinion Leaders (KOLs) and Centres of Excellence (COEs), which are serving to advance the use of the Company's ReCell® Spray-On Skin and provide peer-to-peer training centres for other surgeons.
"Our spray-on regenerative medicine harnesses the body's ability to heal itself and packages it into an easy-to-use bedside kit for clinicians. We are extremely pleased that Avita Medical has established an outstanding group of KOLs and COEs that provide superb grounding and resources in order to commence expansion of our sales and marketing efforts in Europe and Asia," said William Dolphin, Ph.D., CEO of Avita Medical.
More than 4,000 patients have been treated with ReCell, for treatment of burns, hypo- and hyper-pigmentation (e.g., Vitiligo, a common skin pigmentation disease), scar revisions (e.g., acne), and aesthetic skin rejuvenation procedures (e.g., wrinkle removal). Use of ReCell has been clinically demonstrated to improve outcomes, reduce morbidity, and reduce length of hospital stay and patient care costs.
Newly appointed ReCell distribution partners in Russia, The Netherlands and Portugal include:
Russia: JSC Intermedics, an important medical distributor within Russia, employing more than 130 people for the sale and marketing of medical products throughout Russia.
Portugal: Aviquimica, a market-leading Portuguese company in the promotion and sales of consumer medical and hospital equipment.
The Netherlands: Laser Vision, which is extremely well-positioned within the cosmetic dermatology field thanks to the exclusive representation of Lumenis Ltd., the world's largest medical laser company.
ABOUT AVITA MEDICAL LTD.
Avita Medical (www.avitamedical.com) is a publicly listed medical technology company that develops and distributes regenerative and tissue-engineered products for the treatment of a broad range of wounds, scars and skin defects. Using patented and proprietary tissue-culture, collection and application technology, the company is able to provide innovative treatment solutions derived from a patient's own skin. The company's lead product, ReCell® Spray-On Skin, has been designed for use in a wide variety of burns, plastic, reconstructive and cosmetic procedures.
ReCell® is patented, CE marked for Europe, TGA registered in Australia, and SFDA cleared in China. Avita Medical, with funding from the U.S. Department of Defense, is currently conducting U.S. FDA trials for clearance of ReCell for sales within the U.S. market.
Ronald Trahan Associates Inc.
Ronald Trahan, APR, +1-508-359-4005, x108
The Company has been focussing its international sales and marketing efforts on working closely with key, highly regarded surgeons in these countries in order to develop a select group of Key Opinion Leaders (KOLs) and Centres of Excellence (COEs), which are serving to advance the use of the Company's ReCell® Spray-On Skin and provide peer-to-peer training centres for other surgeons.
"Our spray-on regenerative medicine harnesses the body's ability to heal itself and packages it into an easy-to-use bedside kit for clinicians. We are extremely pleased that Avita Medical has established an outstanding group of KOLs and COEs that provide superb grounding and resources in order to commence expansion of our sales and marketing efforts in Europe and Asia," said William Dolphin, Ph.D., CEO of Avita Medical.
More than 4,000 patients have been treated with ReCell, for treatment of burns, hypo- and hyper-pigmentation (e.g., Vitiligo, a common skin pigmentation disease), scar revisions (e.g., acne), and aesthetic skin rejuvenation procedures (e.g., wrinkle removal). Use of ReCell has been clinically demonstrated to improve outcomes, reduce morbidity, and reduce length of hospital stay and patient care costs.
Newly appointed ReCell distribution partners in Russia, The Netherlands and Portugal include:
Russia: JSC Intermedics, an important medical distributor within Russia, employing more than 130 people for the sale and marketing of medical products throughout Russia.
Portugal: Aviquimica, a market-leading Portuguese company in the promotion and sales of consumer medical and hospital equipment.
The Netherlands: Laser Vision, which is extremely well-positioned within the cosmetic dermatology field thanks to the exclusive representation of Lumenis Ltd., the world's largest medical laser company.
ABOUT AVITA MEDICAL LTD.
Avita Medical (www.avitamedical.com) is a publicly listed medical technology company that develops and distributes regenerative and tissue-engineered products for the treatment of a broad range of wounds, scars and skin defects. Using patented and proprietary tissue-culture, collection and application technology, the company is able to provide innovative treatment solutions derived from a patient's own skin. The company's lead product, ReCell® Spray-On Skin, has been designed for use in a wide variety of burns, plastic, reconstructive and cosmetic procedures.
ReCell® is patented, CE marked for Europe, TGA registered in Australia, and SFDA cleared in China. Avita Medical, with funding from the U.S. Department of Defense, is currently conducting U.S. FDA trials for clearance of ReCell for sales within the U.S. market.
Ronald Trahan Associates Inc.
Ronald Trahan, APR, +1-508-359-4005, x108
© Business Wire 2011
댓글 없음:
댓글 쓰기